investor tour visit servic sea md
pleas refer disclosur appendix analyst certif import disclosur price chart
disclosur specif cover compani avail
contact leerink partner editori depart statement valuat risk avail note
follow public contact leerink partner editori depart rx trend deriv im
medic meet radiolog societi north america life scienc biolog
engin intern confer societi urolog oncolog world vaccin
immunotherapi congress intern feder adipos therapeut scienc
asian pacif societi respirolog
ttr amyloidosi medacorp survey result tafamidi take lion
bottom line medacorp survey transthyretin ttr amyloidosi treat physician indic
broad rapid adopt oral ttr stabil tafamidi across hereditari wild type ttr patient
physician enthusiast treat elig patient oligonucleotid therapi oligo patisiran
inotersen show clear prefer two result support two key view
ttr market market segment larg popul patient mostli
cardiomyopathi symptom receiv oral therapi smaller remain popul patient oligo
therapi within oligo segment market share split approxim evenli
inotersen patisiran
survey captur predominantli cardiologist amyloidosi specialist treat numer wild-typ
physician anticip increas patient ttr stabil patient type next year though
think commerci realiti littl slower
physician lack clear prefer two approv oligo therapi see approxim even
market share oligo segment
physician optimist oligo effect cardiomyopathi worri off-label use
commerci challeng
physician believ oligo therapi effect wild-typ ttr see higher bar
grow pain initi market perform pt
bottom line initi coverag inc market
perform rate price target pt realist pathway approv drug
medium term optimist givosiran lumasiran transthyretin ttr franchis
main valu driver near-term headwind market concern
view consensu estim patisiran hereditari ttr amyloidosi difficult meet margin
compress heavi royalti burden limit upsid clinic trial success
acceler opex growth test balanc sheet
onpattro patisiran launch near-term headwind
econom long-term challeng
first-in-class may endur advantag lumasiran
givosiran look like winner
revenu million ep dilut
bottom line initi coverag inc outperform op rate
price target pt eido drug candid ttr amyloidosi oral ttr stabil
robust mid-stag clinic evid placebo-control phase studi suggest profil
competit superior tafamidi enter pivot studi fast-follow
potenti best-in-class efficaci oral ttr stabil market estim peak
sale opportun view favor skew risk/reward profil coverag
investor adequ time horizon
ttr market-build larger player posit view
upsid option intellectu properti ip life assumpt
fulli de-risk yield reason conserv assumpt
success pivot trial could attract strateg interest
revenu million ep dilut
bottom line initi coverag market perform mp
rate pt fan shareholder-friendli strategi see attract risk/
reward profil earli pipelin worri mid- near-term consensu number come
pressur competit product launch data readout next year half combin
competit environ earli partner strategi go forward
sidelin share current level
platform partnership strategi see increas competit intens
sma market share like transit competitor spinraza one robust orphan
drug launch histori
competit posit hattr near-term question remain beyond inotersen
cardiometabol program present upsid risk price target
ionis-htt-rx huntington diseas potenti blockbust
revenu million ep dilut
valu gene edit assum outperform pt
bottom line assum coverag intellia outperform op
rate price target pt leader develop crispr-bas therapeut
view attract valu play among gene edit provid robust balanc sheet
trade discount peer see ntla lipid nanoparticl lnp -base deliveri strategi de-
risk lead indic transthyretin-rel ttr amyloidosi promis potenti second
indic liver failur associ defici anticip ttr
program enter clinic ind submiss see potenti de-risk event
regard safeti profil manufactur infrastructur regulatori path platform whole
ttr progress toward ind
liver failur sensibl target mind
manag team transit posit view
ip issu remain sourc nois fundament impact overst
bottom line week hix open enrol sign up track last year
number vs last week although expect enrol like pick sell
season progress toward flattish membership subsid exchang believ op
op expos exchang report low doubl digit membership
exposur cumul mm peopl sign plan new member
compar peopl week last year new member slow may
due deregul short-term individu polici believ could drive growth
impact repeal individu mandat enrol
enrol compar last year improv week
enrol data mix across state key state fl flat tx perform
nation averag exhibit
effectu enrol yoy
weak may due deregul short-term individu polici may drive enrol
exchang
repeal individu mandat add uncertainti though view carrot subsidi
rather mandat primari stabil factor decoupl health risk price
exchang
mco op op expos exchang
despit slowdown expect enrol like pick sell season progress line
last year toward flattish membership subsid exchang
hix enrol analysi avail follow link
clean transcon data ahead transcon hgh result
bottom line market close asnd report posit phase data transcon
c-type natriuret peptid achondroplasia report earn asnd aim
achiev compani deliv unremark safeti result sign cardiovascular advers
event dose test dose-depend sustain level consist once-weekli
formul news come ahead highli anticip phase transcon hgh height trial result
expect could put compani closer commerci territori parallel compani
act vision expand global format joint
ventur investor syndic led capit announc earlier month
increas po transcon adjust opex rais pt
reiter market perform
transcon seem safe sign cardiovascular advers event dose test
transcon possess infusion-lik profil design
asnd extend transcon technolog global greater china format visen
asnd equiti ownership
revenu million ep
focus multipl shot goal strategi evolv compani
use discount rate termin growth rate
bottom line follow investor meet host chief scientif offic dr steve romano
increment posit headwind acthar unlik increas
forese futur data readout could help potenti stabil even revers
volum trend past month multipl asset pipelin compani start
transform revenu mix particularli program like stratagraft terlipressin phase
trial design intern believ recent pull-back stock respons concern
around acthar efficaci nephrot syndrom link report overdon
see impact acthar volum maintain market perform rate stock pt
recent data provid littl readthrough acthar valu proposit nephrot syndrom ns
acthar sever trial readout help defin appropri patient
inomax competit praxair appear inevit manag believ
prepar defend franchis
busi pipelin year mani catalysts/advanc
amazon tough hill climb disrupt medic record analyt
bottom line believ new effort sell advanc analyt softwar healthcar
provid mine electron health record help cut cost improv clinic care face
stiff competit incumb provid particular believ effort
challeng catch artifici intellig ai machin learn ml power
individu health record ihr combin dispar phenotyp genom data across
claim clinic remot monitor ihr technolog solut embed directli
physician workflow address patient need point care close integr benefit
design provid network wide expect new initi report wsj last night
link cnbc first report secret lab work medic record analyt
solut back june link
construct new front healthcar underway deal
bottom line formal complet acquisit aetna aet mp remain
confid abil execut plan creat new front door healthcar
remain one top pick given strong market posit posit outlook
strategi post-merg maintain op rate
comprehend medic sound market alreadi
bottom line amazon recent foray healthcar warrant watch
believ compani new softwar present signific threat entrench electron
medic record vendor medical-surg distributor pharma suppli chain
amazon comprehend medic unveil week detail wall street journal articl
allow captur unstructur protect health inform record
though variou applic technolog believ offer anoth
step amazon quest creat healthcar ecosystem focus drive target sale
pharmaceut product medic suppli view appar ambit remain
lofti take time given complex healthcar industri continu believ
warrant watch compani remain long-term threat believ
major vendor data system solut mine data
structur unstructur solut popul health manag platform
may heavi compani invest signific dollar analyt
decis support develop workflow believ amazon difficult time
break market meaning manner streamlin revenu cycl may sound good
news articl web-pag patient account solut extraordinarili complex
mani product market layer revenu cycl enhanc cash flow
perform
termin srivastava ceo
bottom line announc file morn ceo
srivastava termin without caus ceo assum duti
role guidanc re-affirmed schedul financi guidanc dec
expect may continu face challeng execut result three
guid down year recent downgrad mp lower pt
sale slightli behind model earn delay may neg indic
bottom line morn reschedul earn releas
confer call report net sale slightli behind
estim roughli in-lin consensu manag cite reschedul date
provid compani independ account firm addit time evalu
impact appreci share associ joint ventur invest appar
process take time expect given recent account pronounc remain
cautiou share head earn amid price pressur headwind higher
take step back put best foot forward swap
dcf analysi discount rate termin growth rate
bottom line market close provid compani updat follow end
phase meet fda lead program ulcer coliti uc result
fda request dose-rang work enter phase
decid switch back-up higher potenc better
target engag preclin studi although switch may introduc risk sinc
preclin drug candid test human believ swap could help
deliv superior clinic efficaci increasingli competit landscap provid extens
develop guidanc across program adjust model accordingli
updat project timelin includ push back launch
lower pt reiter outperform
revenu report ep
bottom line announc execut leadership chang appoint saum sutaria md
newli creat role current presid hospit oper eric evan leav
year-end also reiter guidanc newli creat posit directli
overse hospit oper includ hospital-affili outpati center employ
physician well work enterpris wide strateg initi dr sutaria previous work
mckinsey compani year senior partner provid advisori support hospit health
system asc well work institut investor healthcar also reiter
guidanc believ could see upsid ambulatori out-performance continu turnaround
hospit oper
graduat day initi genet medicin
behold initi market perform pt
biohaven analyst day recap still multipl shot goal
cash flow discount rate
come initi outperform pt
discount rate termin growth rate
one-trick poni initi coverag outperform pt
preview planner
new standard line myeloma affect
averag method dcf price earn price sale
final approv receiv deal expect close wednesday
trump admin battl lower drug price cont new medicar part
continu action drug price posit pbm neg
unev print focu still epidiolex launch pipelin
sotp cash flow discount rate
consum genom test remain best seller cyber monday
insight dinner convers ceo optum sir andrew witti
remark phase valid tripl combin approach cf
fda hold consist prior read preclin data
analysi use discount rate termin growth rate convert impli market cap
eur usd use month fx averag /em
discuss around approv prospect gener advair posit earn
manag indic complet respons letter june includ minor
label chemistri manufactur control -relat question
submit respons mid-juli standard three month goal date
although hope sinc product prioriti design approv could come
manag emphas addit data requir part respons
remain readi launch upon approv
compani develop varlitinib indic high preval asia includ
biliari tract cancer gastric cancer
asln expect multipl data readout includ
interim readout phase i/ii studi varlitinib gemcitabin cisplatin line
top-lin data global phase ii/iii studi varlitinib folfox co-
interim data ph ii studi dhodh inhibitor acut myeloid leukemia
regulatori settlement behavior health feder state agenc appear like
posit catalyst
negoti remain on-going manag optimist settlement reach
investig state feder regul year
settlement reserv increas pre-tax
dec epo patent challeng relat rubraca ovarian prostat
dec european patent offic epo hear oral argument render
opinion patent challeng camsyl salt patent provid ip protect
eu drug rubraca
challeng file divis sandoz anonym parti contend
epo patent recent grant clovi novel -- argument preliminari
opinion agre cite prior art exist applic file
medacorp specialist review preliminari opinion render april felt
opposit strong argument could result narrow patent claim
claim narrow eu could make invent step difficult
uphold unexpect product attribut may compar broadli potenti
open door prior art consid
view eu patent challeng relev impact potenti
takeout option potenti read-through us exclus
composit matter patent expir without addit patent support drug
intellectu properti ip runway relev us patent howev like
hotli debat even dec goe poorli
sourc leerink research compani inform factset price prior day
fda adcom scienc advisori board circulatori system devic
fda adcom joint anesthet analges drug product drug safeti
north carolina dhh award rfp transit medicaid program manag
may texa hhsc award rfp star plu medicaid manag care program
radiolog societi north america
life scienc biolog engin confer
societi urolog oncolog
intern feder adipos therapeut scienc
asian pacif societi respirolog
american societi hematolog present pst bgne
sadal studi abstract session
abstract paraxysm nocturn hemoglobinuria
american societi health-system pharmacist
intern symposium als/mnd
american societi cell biolog
american colleg neuropsychopharmacolog
investor event pst
investor event celg pst pst
investor event pst webcast bgne pst
manag end sell season
univers coverag
calendar event
model model recent updat pleas contact leerink
repres wish review
american societi hematolog
 preview planner
arql -- flash increment new data disclos abstract present
impress beta-th
-- flash abstract show strong symptom relief advanc sm import
imdz -- flash minor updat abstract market perform
-- flash abstract encourag investor focu remain forward-i
-- flash multipl present full sadal data confer outperform
-- flash data abstract still earli present
-- flash abstract highlight earli efficaci present
 disappoint ctad fade prospect ban bace market
-- flash data thin unconvinc benefit limit carrier
 ctad disclosur unlik bolster amyloid outlook market perform
